<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01315002</url>
  </required_header>
  <id_info>
    <org_study_id>NICSZ001</org_study_id>
    <secondary_id>2008-001362-90</secondary_id>
    <nct_id>NCT01315002</nct_id>
  </id_info>
  <brief_title>Nicotine Effects on Endophenotypes of Schizophrenia</brief_title>
  <official_title>Nicotine Effects on Endophenotypes of Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the effects of nicotine on cognition with the following
      schizophrenia endophenotypes: prepulse inhibition, antisaccades, the continuous performance
      test, spatial working memory and a verbal memory task. Schizophrenia patients, unaffected
      first-degree relatives of schizophrenia patients and healthy controls receive transdermal
      nicotine in a double-blind, placebo-controlled, crossover study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Convergent findings suggest that an altered neuronal nicotinic acetylcholine receptor system
      may contribute to the pathophysiology of schizophrenia. Nicotine consumption through
      cigarette smoking might represent a form of self-medication in schizophrenia as nicotine
      reduces cognitive and physiological deficits in schizophrenia. The present study aims to
      investigate how nicotine affects attentional and executive schizophrenia endophenotypes and
      how genetic polymorphisms relating to the cholinergic system might play a role in
      inter-individual differences in the magnitude of nicotine effects.

      Schizophrenia patients, first-degree relatives of schizophrenia patients as well as healthy
      controls will receive transdermal nicotine in a double-blind, placebo-controlled, crossover
      study and will be assessed with prepulse inhibition, antisaccades, the continuous performance
      test, spatial working memory and a verbal memory task. Subjects will be overnight-abstinent
      smokers and non-smokers. However, the investigators will particularly test non-smokers in
      order to eliminate confounding effects of nicotine withdrawal and reinstatement.

      Main hypotheses:

        -  Schizophrenia patients will perform worse than matched controls in all cognitive tests
           (validating our endophenotypes).

        -  Nicotine administration will enhance cognitive performance in overnight-abstinent
           smokers.

        -  Improvement of cognitive performance in smokers with schizophrenia will be stronger than
           in control smokers.

        -  Improvement of cognitive performance in smoking first-degree relatives of schizophrenia
           patients will be stronger than in control smokers.

        -  Nicotine administration will affect cognitive functioning in non-smoking subjects.

        -  Nicotine administration will improve cognitive functioning in non-smoking schizophrenia
           patients.

        -  The effects of nicotine in non-smoking subjects are stronger in those subjects who are
           cognitively more impaired (i.e. performing below the median of the respective group).

      The present research contributes to the issue whether nicotinic cholinergic receptor agonists
      may have therapeutic value in the treatment of cognition in schizophrenia.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Error Percentage in Antisaccade Task</measure>
    <time_frame>Three hours after patch application</time_frame>
    <description>Three hours after the application of a nicotine or a placebo patch, performance on the antisaccade task is assessed. In the antisaccade task participants visually fixate a central stimulus which is replaced by a sudden onset target that appears at some distance to the left or right. Participants are told to refrain from looking at the peripheral target, and direct their gaze instead in the opposite direction (i.e. they have to make an antisaccade). Participants typically fail to achieve this on a significant number of trials and instead make reflexive glances towards the target (i.e. making a so-called antisaccade error). Error percentage in the antisaccade task is the unit of measure in this task. Error percentage in the antisaccade task = number of antisaccade errors / total number of trials.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>Nicotine Patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transdermal nicotine patch</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo patch</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo patch</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Transdermal nicotine patch</intervention_name>
    <description>7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)</description>
    <arm_group_label>Nicotine Patch</arm_group_label>
    <other_name>NiQuitin Clear, GlaxoSmithKline Germany</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo patch</intervention_name>
    <description>Placebo patch</description>
    <arm_group_label>Placebo patch</arm_group_label>
    <other_name>band-aid by Fink and Walter GmbH, Germany</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients:

          -  Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM IV)
             diagnosis of schizophrenia

          -  age 18-55 years old

          -  able to provide informed consent

          -  treated with antipsychotic medications at a stable dose for at least 6 weeks

          -  normal or corrected to normal vision

          -  smokers (Fagerström Test for Nicotine Dependence &gt; 4)

          -  non-smokers (&lt; 100 cigarettes/lifetime, not having smoked in the past year)

        Controls:

          -  age 18-55 years old

          -  able to provide informed consent

          -  normal or corrected to normal vision

          -  smokers (Fagerström Test for Nicotine Dependence &gt; 4)

          -  non-smokers (&lt; 100 cigarettes/lifetime, not having smoked in the past year)

        Unaffected First-Degree Relatives of Schizophrenia Patients:

          -  same inclusion criteria as controls plus

          -  having an adult first-degree relative (sibling, parent, child) with a DSM IV diagnosis
             of schizophrenia

        Exclusion Criteria:

        Patients:

          -  substance dependence

          -  clinical instability

          -  changes in medication in the last 6 weeks

          -  anticholinergic medication

          -  untreated hypertension

          -  cardiovascular disease

          -  insulin-dependent diabetes mellitus

          -  phaeochromocytoma

          -  uncontrolled hyperthyroidism

          -  renal or hepatic impairment

          -  central nervous system disease

          -  pulmonary disease

          -  generalised dermatological disorders (neurodermatitis, psoriasis, chronic dermatitis,
             urticaria, etc.)

          -  gastric or intestinal ulcer

          -  hypersensitivity to nicotine

          -  allergy to patches

          -  women: pregnancy, lactation

        Controls:

          -  substance dependence

          -  having a first-, second-, or third-degree relative with a psychotic disorder

          -  DSM IV Axis I disorder

          -  anticholinergic medication

          -  untreated hypertension

          -  cardiovascular disease

          -  insulin-dependent diabetes mellitus

          -  phaeochromocytoma

          -  uncontrolled hyperthyroidism

          -  renal or hepatic impairment

          -  central nervous system disease

          -  pulmonary disease

          -  generalised dermatological disorders (neurodermatitis, psoriasis, chronic dermatitis,
             urticaria, etc.)

          -  gastric or intestinal ulcer

          -  hypersensitivity to nicotine

          -  allergy to patches

          -  women: pregnancy, lactation

        Unaffected First-Degree Relatives of Schizophrenia Patients:

          -  same exclusion criteria as controls
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Wagner, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Maier, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 14, 2011</study_first_submitted>
  <study_first_submitted_qc>March 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2011</study_first_posted>
  <results_first_submitted>December 18, 2014</results_first_submitted>
  <results_first_submitted_qc>January 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 16, 2015</results_first_posted>
  <last_update_submitted>January 7, 2015</last_update_submitted>
  <last_update_submitted_qc>January 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Nadine Petrovsky</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>nicotine</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>endophenotype</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nicotine First, Then Placebo</title>
          <description>Transdermal nicotine patch first (single application), then placebo patch (single application, one week after administration of nicotine patch)
Doses:
non-smokers: 7mg transdermal nicotine patch smokers: 14mg transdermal nicotine patch</description>
        </group>
        <group group_id="P2">
          <title>Placebo First, Then Nicotine</title>
          <description>Placebo patch first (single application), then transdermal nicotine patch (single application, one week after administration of placebo patch)
Doses:
non-smokers: 7mg transdermal nicotine patch smokers: 14mg transdermal nicotine patch</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="60"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Includes groups randomized to receive nicotine first and placebo first. Number of all study participants = 121.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.23" spread="9.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Error Percentage in Antisaccade Task</title>
        <description>Three hours after the application of a nicotine or a placebo patch, performance on the antisaccade task is assessed. In the antisaccade task participants visually fixate a central stimulus which is replaced by a sudden onset target that appears at some distance to the left or right. Participants are told to refrain from looking at the peripheral target, and direct their gaze instead in the opposite direction (i.e. they have to make an antisaccade). Participants typically fail to achieve this on a significant number of trials and instead make reflexive glances towards the target (i.e. making a so-called antisaccade error). Error percentage in the antisaccade task is the unit of measure in this task. Error percentage in the antisaccade task = number of antisaccade errors / total number of trials.</description>
        <time_frame>Three hours after patch application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nicotine Patch</title>
            <description>Transdermal nicotine patch
Transdermal nicotine patch: 7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Patch</title>
            <description>Placebo patch
Placebo patch: Placebo patch</description>
          </group>
        </group_list>
        <measure>
          <title>Error Percentage in Antisaccade Task</title>
          <description>Three hours after the application of a nicotine or a placebo patch, performance on the antisaccade task is assessed. In the antisaccade task participants visually fixate a central stimulus which is replaced by a sudden onset target that appears at some distance to the left or right. Participants are told to refrain from looking at the peripheral target, and direct their gaze instead in the opposite direction (i.e. they have to make an antisaccade). Participants typically fail to achieve this on a significant number of trials and instead make reflexive glances towards the target (i.e. making a so-called antisaccade error). Error percentage in the antisaccade task is the unit of measure in this task. Error percentage in the antisaccade task = number of antisaccade errors / total number of trials.</description>
          <units>Error Percentage in Antisaccade Task</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="17.0"/>
                    <measurement group_id="O2" value="29.1" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis is that there was no difference in change of error percentage in the antisaccade task between nicotine and placebo. An ANOVA model was used with treatment (nicotine, placebo) as a within-subjects factor. The test was performed with a significance level of 0.05 (two-sided). Results showed significantly better antisaccade performance (i.e. less antisaccade errors) in the nicotine condition.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years, 8 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Nicotine First, Then Placebo</title>
          <description>Transdermal nicotine patch first (single application), then placebo patch (single application, one week after administration of nicotine patch)
Doses:
non-smokers: 7mg transdermal nicotine patch smokers: 14mg transdermal nicotine patch</description>
        </group>
        <group group_id="E2">
          <title>Placebo First, Then Nicotine</title>
          <description>Placebo patch first (single application), then transdermal nicotine patch (single application, one week after administration of placebo patch)
Doses:
non-smokers: 7mg transdermal nicotine patch smokers: 14mg transdermal nicotine patch</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Dr. Michael Wagner</name_or_title>
      <organization>University Hospital Bonn, Department of Psychiatry and Psychotherapy</organization>
      <phone>004922828716377</phone>
      <email>michael.wagner@uni-bonn.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

